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Whole body MR in patients with multiple 
myeloma
Alina PIekARek, Piotr sOsNOWskI, Adam NOWIckI, Mieczysław 
kOMARNIckI
AbstrAct
bAckground: Multiple myeloma is a cancer of plasma cells which leads to bone marrow 
infiltration.
Aim: Whole-body MR is the most sensitive imaging method available to detect multiple myeloma 
lesions.
mAteriAl And methods: MR scans were performed in 100 patients with multiple myeloma who 
were receiving treatment in the Haematology Clinic in Poznań in the years 2005–2006. Whole-body 
MR scans were performed with general coil 1.0 T in STIR sequences and T1 sequences, in coronal 
and sagittal planes with scanning area covering the head, neck, trunk and the limbs (FOV for specific 
regions was 36–48 cm). The bone lesions were classified as focal (monofocal/multifocal lesions), in-
filtrative, mixed and “salt and pepper” type. Depending on the size of the lesions the patients were 
included in one of three groups according to Salmon-Durie Plus classification.
results: Four main types of multiple myeloma were distinguished based on MR scans: focal (48 pa-
tients; monofocal in 10 patients), infiltrative (17 patients), mixed type (19 patients) and “salt and pep-
per” type (4 patients). The remaining 12 patients had no multiple myeloma lesions in the bone mar-
row. Additionally, in 18% of patients a soft tissue mass could be observed. According to Salmon-Durie 
Plus categorisation 27 subjects were classified as having stage I, 16 patients stage and 57 patients 
stage III disease. In 12% of patients MR data changed the disease staging.
conclusions: WB MR is a sensitive and effective diagnostic method with an important impact on 
staging and further treatment of multiple myeloma.
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bAckground
Multiple myeloma (myeloma multiplex) is a ma-
lignant neoplasm of plasma cells which invade 
the bone marrow. Multiple myeloma constitutes 
about 1% of all neoplasms and about 13% of blood 
neoplasms. The disease may invade the skeleton 
and the kidneys, may impair immune system 
function and may lead to haematological abnor-
malities. Prognosis depends on disease stage, 
particularly at the time of diagnosis. Treatment 
involves chemotherapy and bone marrow trans-
plant, as well as radiotherapy. 
Aim
Whole-body MR (WB MR) is the most sensi-
tive imaging method available to detect mul-
tiple myeloma lesions.
mAteriAls And methods
Whole-body MR scans were performed in 100 
subjects with multiple myeloma (39 females 
and 61 males; age 32 to 79 years; mean age 
59.22 years) who were receiving treatment in 
the Haematology Clinic in Poznań University 
of Medical Sciences in the years 2005–06. In 
62 patients WB MR was performed before the 
initiation of the treatment, whereas the re-
maining 38 patients had their WB MR scans 
performed during multi-phase treatment 
(after chemotherapy, bone marrow trans-
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plant and/or radiotherapy). The time period 
between WB MR and treatment completion 
ranged from 3 to 21 days (17 days on average) 
and it was dependent on the disease stage, 
overall patient condition and the availability 
of WB MR.
Whole-body MR scans were performed 
using a general coil 1.0 T MR apparatus in 
STIR sequences (TR 2700 ms, TE 50 ms, TI 
110 ms) and T1 sequences (TR 450 ms, TE 
50 ms), in coronal and sagittal planes, cov-
ering the head, neck, trunk and the upper 
and lower limbs to the knee level (FOV for 
specific regions ranged from 36 to 48 cm). 
Additional sequences were performed in 19 
patients with sporadic lesions detected in the 
head, abdomen and the joints. Bone marrow 
status was graded 0–2, both for focal and for 
infiltrative lesions, where:
0 = No lesions
1 =Uncertain lesions (indirect signal in STIR 
and/or T1 sequences)
2 =Certain lesions (significantly high signal 
in STIR sequences and significantly low sig-
nal in T1sequences)
The number of focal lesions for a specific 
body region was determined and the lesion 
area was subjectively categorized as “no in-
filtration”, “minor infiltration” and “exten-
sive, homogeneous infiltration”. Depending on 
the extent of the lesions the patients were in-
cluded in one of three groups according to the 
Salmon-Durie Plus classification. (Table 1)
results
Whole-body MR scans allowed four main types 
of multiple myeloma to be distinguished: 
1. Focal type (high signal foci in STIR se-
quences and low signal foci in T1 sequenc-
es) was. „observed in 48 patients, including 
monofocal type – detected in 10 patients. The 
smallest. _foci of <1 cm diameter were found 
in skull bones, whereas the largest foci of >4 
cm diameter were detected in pelvic bones 
(Fig. 1–2)*
2. Infiltrative type (homogeneous infiltra-
tion of high signal in STIR sequences and low 
signal in T1 sequences) – detected in 17 pa-
tients (Fig. 3)
* Noother focal lesions were taken into account (for instance angiomas of thoracic and lumbar vertebrae with high 
signal T1 and STIR (T2-W).
3. Mixed type (diffuse foci seen against the 
infiltrative lesion background) – detected in 
19 patients
4. “Salt and pepper” type (with high signal 
fat islets in T1 sequences) – detected in 4 pa-
tients
The remaining 12 patients had no multiple 
myeloma lesions in the bone marrow.
In 18% of our patients a soft tissue mass 
Table 1. Salmon-Durie Plus classification of multiple myeloma 
lesions
I 0–4 foci and/or absence of infiltration in MR/PET scans
II 5–20 foci and/or minor infiltration in MR/PET scans
III >20 foci and/or extensive, massive infiltration in MR/PET scans
A: creatinine <2 mg/dl   B: creatinine >2 mg/dl
Fig. 1. Multifocal lesions, Stage III: b – sagittal STIR image: high 
signal focal lesions in the skull, sternum and vertebral bodies with 
collapsed Th2, c – sagittal SE T1-W image: low signal lesions in 
the sternum and vertebral bodies
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was observed, usually located paravertebral-
ly or in the pelvis. (Fig. 2). Forty-five sub-
jects suffered from the fracture of at least 
one thoracic vertebra and 28 experienced 
fractures of lumbar vertebrae. Femoral frac-
ture occurred in 3 subjects. Of the total num-
ber of fractures (141), 95% involved the axial 
skeleton. According to Salmon-Durie Plus 27 
patients were classified as having stage I, 16 
patients stage II and 57 patients stage III dis-
ease (Table 2).
Disease staging as determined by clinicians 
based on biochemical markers and standard 
radiological scans was changed in 12 patients, 
of which 8 were re-classified to a higher stage 
and 4 to a lower stage of multiple myeloma.
discussion
„The reference whole-body MR protocol for 
multiple myeloma patients comprises two se-
quences, i.e. STIR and SE T1, in coronal and 
sagittal planes [1–4].
Typical multiple myeloma lesions yield a 
significantly high signal in STIR sequences 
and a low signal in T1 sequences [3, 5–7]. Bone 
marrow infiltration is manifested by means of 
diffuse foci or infiltrative lesions which may 
be accompanied by pathological fractures of 
the axial skeleton [4–9].
A B
Fig. 2. Local mass in the right iliac bone over 9 cm in diameter: 
a – coronal STIR image, b – coronal SE T1-W image
A B
Fig. 3. Homogeneous infiltration, Stage III: a – sagittal T1-W 
image, low signal of the bone marrow in the sternum and in the 
spine; b – sagittal STIR image, high signal of the bone marrow
Table 2. Clinical vs. MRI staging: changes of staging – lower (L), 
higher (H) Clinical Staging MRI Staging
I stage 23 27
II stage 28 (4L) 16 (8H) 
III stage 49 57
Fig. 4. Multifocal lesions, Stage III: a – coronal 
STIR, high signal lesions in the spine, pelvis, skull
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Based on the results of investigations of 77 
subjects Baur-Melnyk et al. [7] distinguished 
the following types of the disease: focal multi-
ple myeloma in 30% of patients, homogeneous 
infiltration in 38% of patients, mixed type le-
sions in 11% of patients and “salt and pepper” 
type of disease (with high signal fat islets in 
T1 sequences) in 3% of patients. In 28% of sub-
jects bone marrow presentation was normal, 
but that did not exclude the diagnosis of mul-
tiple myeloma.
In our study material focal lesions were 
found in 48% of patients, homogeneous infil-
tration in 17% of patients, mixed type lesions 
in 19% of patients and “salt and pepper” type 
of lesions in 4% of patients. Clinical staging 
in most of our patients was advanced and in 
this stage multifocal lesions dominated (Fig. 
1). In 18% of patients a soft tissue mass could 
be observed extravertebrally. In 12 subjects 
no bone marrow lesions could be observed; 
they were classified as stage I (Salmon-Durie 
Plus).
Pathological fractures primarily involved 
the axial skeleton in our study, but in less 
than 50% of cases (67/141) they were associ-
ated with focal or infiltrative lesions. Lecou-
vet et al. [9] proved that not every fracture 
in multiple myeloma patients is related to 
visible infiltration of the bonemarrow and in 
their study infiltrative lesions were associ-
ated only in 46% of fracture cases. This ex-
plains the low specificity of standard radiog-
raphy [3, 4, 7, 8]
Whole-body MR scanning is an independent 
factor that can change both disease staging 
and prognosis, which has been reflected in the 
modification of the three-stage Salmon-Durie 
classification [1]. High sensitivity of MR in 
detecting bone marrow lesions is of particular 
importance in situations when conventional 
imaging does not reveal any abnormalities. 
This early stage of the disease, i.e. “smoulder-
ing disease”, does not require treatment, as 
a “watch and wait strategy” has been proved 
sufficient [7, 10]. Patients with stage I disease 
in whom MR scans reveal no lesions (12% of 
subjects in our study), patients with less than 
4 foci and patients with “salt and pepper” type 
of lesions do not require chemotherapy. In an 
active form of multiple myeloma with exten-
sive bone marrow infiltration WB MR can 
reveal massive infiltrations or verynumerous 
(often incalculable) foci that are dispersed 
throughout the whole skeletal system [7]. In 
our study material, in 8 subjects WB MR re-
vealed more advanced disease as compared 
to its clinical staging. Four patients, classified 
first to stage II of disease, after WB MR were 
re-classified as stage I and no treatment was 
needed (“watch and wait strategy”).
Some authors emphasize the high sensitiv-
ity of T1 SE fat-saturated scans with contrast 
enhancement, particularly in patients with a 
high degree of bone marrow infiltration [3, 7, 
11] and in recently diagnosed, pre-treatment 
cases. These scans and control studies seem 
to be of particular value in monitoring the ef-
ficacy of treatment.
conclusions
WB MR is a sensitive and effective diag-
nostic method with an important impact on 
staging and further treatment of multiple 
myeloma.
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